Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|October 7, 2020
2021 Event Details for CPhI and Pharmapack Europe Released
Author(s)Pharmaceutical Technology Editors
A complete listing of event dates for CPhI and Pharmapack Europe 2021 has been released.
Advertisement
On the opening day of the CPhI Festival of Pharma, event organizers, Informa Markets, announced a complete listing of event dates for 2021, which will include both live and hybrid events.
In an Oct. 5, 2020 press release, the schedule was detailed and includes eight international CPhI events and Pharmapack Europe. All the 2021 events will be enhanced by digital elements.
“We are thrilled about coming together with the pharma community again at CPhI Festival of Pharma, and we wanted to give details of all our pharma events for the year ahead,” said Adam Andersen, group director of the Pharma Portfolio at Informa Markets, in the press release. “In 2021 we are implementing a hybrid model of events delivery, with virtual and online offerings, as well as live editions to provide greater flexibility to pharma companies and executives.”
The full list of confirmed dates can be found below:
- Dec. 16–18, 2020: CPhI China (hybrid, live + virtual)
- Jan. 27–29, 2021: CPhI India
- Apr. 14–16, 2021: CPhI Japan
- May 19–20, 2021: Pharmapack Europe
- June 22–24, 2021: CPhI China
- Aug. 4–6, 2021: CPhI SEA
- Aug. 10–12, 2021: CPhI North America
- Aug. 31–Sep. 2, 2021: CPhI Worldwide
- Sep. 26–28, 2021: CPhI MEA
- Oct. 11–13, 2021: CPhI Korea
- Nov. 23–25, 2021: CPhI India
Source:
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement